Versant Venture Management
CTNM icon

Versant Venture Management’s Contineum Therapeutics CTNM Stock Holding History

Versant Venture Management’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$17.3M Buy
1,292,628
+750,000
+138% +$11.2M 15.9% 3
2026
Q2 		$8.89M Hold
542,628
– – 5.47% 5
2026
Q1 		$7.09M Hold
542,628
– – 5.01% 5
2025
Q4 		$6.2M Hold
542,628
– – 4.11% 5
2025
Q3 		$6.38M Hold
542,628
– – 3% 6
2025
Q2 		$2.15M Sell
542,628
-375,535
-41% -$1.63M 2.62% 6
2025
Q1 		$6.41M Hold
918,163
– – 10.64% 3
2024
Q4 		$13.5M Hold
918,163
– – 15.51% 3
2024
Q3 		$17.6M Hold
918,163
– – 27.64% 2
2024
Q2 		$16.2M Buy
+918,163
New +$14.8M 20.92% 2

Other funds holding CTNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Sectoral Asset Management
Sectoral Asset Management Montreal, Quebec, Canada $157M AUM 41.41% 1-Year Est. Return
Red Tree Management
Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Versant Venture Management's CTNM Position: Q3 2026 in Review

Versant Venture Management increased its Contineum Therapeutics (CTNM) stake by 138% in Q3 2026, buying an estimated $11.2M and bringing the position to 1,292,628 shares worth $17.3M. The position accounts for 15.9% of the portfolio, ranked #3.

Versant Venture Management first reported a position in CTNM in Q2 2024 and has held it in 10 quarters since. The position peaked at $17.6M in Q3 2024. 63 funds tracked by Wall St. Rank hold CTNM as of Q3 2026.

  • Versant Venture Management held 1,292,628 shares of Contineum Therapeutics worth $17.3M as of Q3 2026.
  • Versant Venture Management bought 750,000 Contineum Therapeutics shares in Q3 2026, an estimated $11.2M.
  • Contineum Therapeutics made up 15.9% of Versant Venture Management's portfolio in Q3 2026, its #3 holding.
  • Versant Venture Management first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • Versant Venture Management's Contineum Therapeutics position peaked at $17.6M in Q3 2024.
  • 63 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q3 2026.

Based on Versant Venture Management's 13F filing for Q3 2026, filed 13 Nov 2026.